Table 1.
Demographic characteristics and clinical presentations of Mycoplasma-induced rash and mucositis.
| P1 | P2 | P3 | P4 | P5 | |
|---|---|---|---|---|---|
| Age/gender | 6 y/F | 7 y/M | 3 y3 m/F | 2 y5 m/M | 7 y/M |
| Previous diagnosis | Erythema multiforme | Erythema multiforme | Erythema multiforme exudativum | Erythema multiforme exudativum | Erythema multiforme |
| Fever duration | 3 days | 4 days | 5 days | 6 days | 11 days |
| Inpatient duration | 9 days | 4 days | 6 days | 10 days | 11 days |
| Respiratory symptoms | Slightly cough | No | Cough | No | Cough and sputum |
| Rash morphology | Macules, maculopapular, vesiculobullous | Macules, targetoid | Macules, maculopapular, vesiculobullous (d = 3 cm) | Maculopapular, vesiculobullous (d = 1 cm) | Maculopapular, vesiculobullous (d = 0.3–1 cm) |
| Cutaneous distribution | Sparse, <10% BSA | Sparse, <10% BSA | Sparse, <10% BSA | Sparse, <10% BSA | Sparse, <10% BSA |
| Cutaneous involvement | Face, hands and feet, rare on trunk and limbs | Face, trunk, limbs | Face, trunk, limbs | Face, trunk, limbs | Face, trunk, limbs, penile meatus |
| Itchiness of rash | / | No itching | Itching | Itching | Itching |
| Mucosal involvement | Oral, ocular, genital, anus | Oral, ocular | Oral, ocular, genital | Oral, ocular, genital, anal | Oral, ocular, genital |
| Treatment | Azithromycin, methylprednisolone (22 days), IVIG (2 g/kg), mucosal care | Azithromycin, methylprednisolone (14 days), ceftriaxone | Azithromycin, methylprednisolone (15days) | Azithromycin, methylprednisolone (15 days), IVIG (2 g/kg), acyclovir, cephalosporin, mucosal care; | Azithromycin; methylprednisolone (14 days), IVIG (1 g/kg), acyclovir, cefuroxime, cefoxitin, mucosal care |
| WBC, × 109/L | 7.0 | 18.5 | 10.0 | 6.5 | 7.6 |
| Neutrophils, % | 61.6 | 90.3 | 62.1 | 44.8 | 82 |
| Lymphocytes, % | 24.5 | 8.7 | 32.2 | 46.8 | 10.1 |
| CRP, mg/L | 60 | 81 | 36 | 39 | 52 |
| ESR, mm/h | 20 | 69 | 36 | 54 | 61 |
| Serum MP-IgM | 1:1,280 | 1:640 | >1:1,280 | >1:1,280 | at admission: N, 1 week later: >1:1,280 |
| Sputum MP-DNA, copies/ml | / | / | / | N | 7.48E+06 |
| Clinical outcomes | Full recovery | Full recovery | |||
| Dermal: | Dyspigmentation | Dyspigmentation | Dyspigmentation | ||
| Ocular: | Full recovery | Full recovery | Recurrent allergic conjunctivitis | ||
| Urogenital: | Full recovery | Full recovery | Genital synechiae (recovery after surgery) | ||
| Follow-up | 29 months | 7 months | 36 months | 32 months | 7 months |
M, male; F, female; IVIG, intravenous immunoglobulins; d, diameter; CRP, C-reactive protein; ESR, erythrocyte sedimentation rate; N, negative; /, Not available.